1Q Preview: Mixed China, Korea Outlook As Policies, Economics Bite
This article was originally published in PharmAsia News
As major companies start to release their quarterly results over the next few weeks, PharmAsia News takes a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia’s major corporate players.
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.